These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23704213)

  • 1. Apolipoprotein C-III: going back to the future for a lipid drug target.
    Huff MW; Hegele RA
    Circ Res; 2013 May; 112(11):1405-8. PubMed ID: 23704213
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ApoCIII: the next PCSK9?
    Bernelot Moens SJ; van Capelleveen JC; Stroes ES
    Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.
    Yamamoto T; Obika S; Nakatani M; Yasuhara H; Wada F; Shibata E; Shibata MA; Harada-Shiba M
    Eur J Pharmacol; 2014 Jan; 723():353-9. PubMed ID: 24269597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Reeskamp LF; Tromp TR; Stroes ESG
    Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volanesorsen: First Global Approval.
    Paik J; Duggan S
    Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.
    Valdivielso P; Coca Prieto I
    Med; 2024 Jun; 5(6):493-494. PubMed ID: 38878767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
    Gaudet D; Alexander VJ; Baker BF; Brisson D; Tremblay K; Singleton W; Geary RS; Hughes SG; Viney NJ; Graham MJ; Crooke RM; Witztum JL; Brunzell JD; Kastelein JJ
    N Engl J Med; 2015 Jul; 373(5):438-47. PubMed ID: 26222559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy: Targeting apoc-III to lower triglycerides.
    Huynh K
    Nat Rev Cardiol; 2015 Feb; 12(2):64. PubMed ID: 25533798
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting APOC3 in the familial chylomicronemia syndrome.
    Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
    N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apolipoprotein C III and hypertriglyceridemia].
    Wang JY
    Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):37-9. PubMed ID: 21417013
    [No Abstract]   [Full Text] [Related]  

  • 16. Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition.
    Syed-Abdul MM; Tian L; Lewis GF
    Arterioscler Thromb Vasc Biol; 2023 Nov; 43(11):2133-2142. PubMed ID: 37675633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism.
    Luo M; Peng D
    Lipids Health Dis; 2016 Oct; 15(1):184. PubMed ID: 27770802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triglycerides on the rise: should we swap seats on the seesaw?
    Libby P
    Eur Heart J; 2015 Apr; 36(13):774-6. PubMed ID: 25548060
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene therapy. Inhibiting apoC-III synthesis in patients with hypertriglyceridaemia.
    Huynh K
    Nat Rev Cardiol; 2015 Oct; 12(10):562. PubMed ID: 26283267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.